OnKure Therapeutics, Inc. Class A Common Stock (OKUR) is a publicly traded Healthcare sector company. As of May 21, 2026, OKUR trades at $3.64 with a market cap of $124.42M and a P/E ratio of -0.83. OKUR moved +8.18% today. Year to date, OKUR is +24.04%; over the trailing twelve months it is +53.45%. Its 52-week range spans $1.70 to $20.00. Analyst consensus is strong buy with an average price target of $24.33. Rallies surfaces OKUR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
OnKure Secures $150M, Advances OKI-355 and OKI-345 Candidates: OnKure closed a $150 million private placement, boosting cash to $192.1 million as of March 31, 2026, to fund operations into 2029. The company nominated two next-generation PI3Kα pan-mutant inhibitors—OKI-355 for vascular anomalies and OKI-345 for breast cancer—with IND applications planned in H1 2027.
| Metric | Value |
|---|---|
| Price | $3.64 |
| Market Cap | $124.42M |
| P/E Ratio | -0.83 |
| EPS | $-4.33 |
| Dividend Yield | 0.00% |
| 52-Week High | $20.00 |
| 52-Week Low | $1.70 |
| Volume | 17 |
| Avg Volume | 0 |
| Revenue (TTM) | $2.82M |
| Net Income | $-58.75M |
| Gross Margin | 0.00% |
4 analysts cover OKUR: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.33.